Coiffier, Bertrand <br/><br/>
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.  [electronic resource] 

 -  The Lancet. Oncology  Aug 2011 
 - 773-84 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(11)70150-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Infusion Pumps<br/>Lymphoma, Follicular--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Pyrazines--administration & dosage<br/>Recurrence<br/>Rituximab<br/>Young Adult